Direction: Alain PUISIEUX



To visit the CRCL website : click here

The Cancer Research Centre of Lyon (CRCL) is a new research institution labelled by Inserm, the CNRS, the Université Lyon 1, the Centre Léon Bérard (CLB) and with the Hospices Civils de Lyon (HCL) as hospital partner. The CRCL opened its doors in January 2011 after receiving the green light from the French Evaluation Agency for Research and Higher Education (AERES) in 2010. The CRCL comprises 17 teams, totalling 370 people, including 110 researchers and teaching researchers on three sites in the immediate vicinity: the Centre Léon Bérard (Cheney A and Cheney D buildings), the Inserm buildings on Cours Albert Thomas and the Rockefeller Faculty of Medicine and Pharmacy, all based in the east of Lyon. The aim of the CRCL is to expand the international reputation and outreach of the research centre, stimulate knowledge transfer to the clinic and develop teaching and training.

The CRCL is organised around three scientific departments focused on the following research priorities:
Tumoral escape (Managed by Patrick Mehlen and assisted by Jean-Yves Scoazec)
Information flow in the cancer cell (Managed by Gilles Thomas and assisted by Didier Auboeuf)
Immunity, Microenvironment, Virus (Managed by Christophe Caux & Fabien Zoulim)

The CRCL teams can rely on state-of-the-art technical equipment (cell sorting and cytometry platform, L3 laboratory, tumour model laboratory, related technological platforms on the Lyon-Est site) and shared services (administrative management unit, washing room, etc.) to support their projects. Once projects have been evaluated, the research teams also benefit from financial support from cancer associations (ARC and the French National Cancer League), INCa, ANR, ANRS, the CLARA cluster, the Lyon Biopôle competitiveness cluster, industrial partnerships or the European Union.

One of the goals of the CRCL is to support the development of strong translational research to enable patients to benefit from breakthroughs in basic research as rapidly as possible. This crossover is rendered possible due to the dedication of clinicians and pathologists from the CLB and HCL within scientific teams, creating a seamless continuum between basic research and clinical applications.

By pursuing your navigation on our website, you accept the use of cookies for our statistics - Close
cliquez-ici
eskisehir escort balikesir escort